We appreciate Dr Tsuda's comments and observations on the involvement of nitric oxide in leptin-induced endothelial dysfunction and cardiac failure. We agree with Dr Tsuda that similar mechanisms might occur in neonatal leptin-treated rats. Because endothelial dysfunction represents an early form of vascular disease that precedes other cardiovascular complications, the role of neonatal leptin on endothelial function may provide valuable mechanistic insights.
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Although we will be proposing to conduct these analyses, we will also investigate the role of the overactive sympathetic nervous system in the neonatal leptin-treated rats, 1 which may influence vascular tone and cardiac function. Recent study by Wang et al 2 demonstrates that endothelial dysfunction in leptin-induced mice is blocked by mesenteric sympathetic denervation. Interestingly, also superoxide scavanger TEMPOL (4-hydroxy-2,2,6,6-tetrametylpiperidin-1-oxyl) treatment had similar therapeutic effects and suggests reactive oxygen species and sympathetic outflow as potential targets for leptin-induced endothelial dysfunction and hypertension. 2 Leptin has also shown a negative inotropic effect in the heart, which has been shown to be dependent on nitric oxide and STAT-3 (signal transducer and activator of transcription 3)-induced p38 mitogen-activated protein kinase activation. 3, 4 These mechanistic pathways will be considered in future work, as well as potential targets, which mediate the adverse cardiac effects secondary to neonatal hyperleptinemia.
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